You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
和铂医药(02142.HK)新抗体在澳洲开展之临床研究完成首例患者给药
阿思达克 05-11 16:35
和铂医药(02142.HK)公布,其HBM4003针对澳大利亚患有晚期黑色素瘤、肝癌(HCC)、肾癌(RCC)及其他瘤种患者的I期第2部分(「Ib/IIa期」)临床研究已完成首例患者给药。

该研究将评估HBM4003作为单药治疗多种实体瘤的安全性、耐受性、药代动力学/药效动力学(PK/PD)及抗肿瘤疗效。临床I期第1部分研究结果已向欧洲肿瘤医学学会递交。作为公司的新一代抗CTLA-4抗体,HBM4003目前正在全球开展针对晚期实体瘤患者的开放性、多中心临床试验。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account